[Clinical experiences with vasoatherolip in early cerebral insufficiency].
Under clinical conditions and during 12 weeks Vasoatherolip (alufibrat and nicotinuric acid) were administered to a group of 30 patients suffering from definitive symptoms of early cerebral insufficiency. The daily dosage was 3 X 1 tablet. In about 66 per cent of the patients a significant improvement, especially for intellectual and affective capacity was achieved. This could be proved by a number of confirmed psychometrical tests (i.e. concentration-test, Benton-test, pegboard-test, Wechsler-test, etc.).
D000368:Aged; D000535:Aluminum / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy*; D002994:Clofibrate / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011594:Psychometrics
D009539:Nicotinic Acids; D000535:Aluminum; D002994:Clofibrate
Klinische Erfahrungen mit Vasoatherolip bei zerebraler Frühinsuffizienz